Cancer Biomarkers - Volume 13, issue 5

Authors: Mazurek, Agnieszka M. | Fiszer-Kierzkowska, A. | Rutkowski, T. | Składowski, K. | Pierzyna, M. | Ścieglińska, D. | Woźniak, G. | Głowacki, G. | Kawczyński, R. | Małusecka, E.

Article Type: Research Article

Abstract: Background: The precise analysis of tumour markers in blood such as circulating cell-free DNA (cfDNA) could have a significant impact in facilitating monitoring of patients after initial therapy. Although high levels of total cfDNA in plasma of cancer patients are consistently demonstrated, a low sensitivity of DNA alterations is reported. Objective: The major question regards the recovery of tumour-specific cfDNA such as KRAS mutated DNA and cancer-associated type 16 of human papillomavirus (HPV16). Methods: TaqMan technology was used for detection of KRAS mutation, HPV16 and to quantify cfDNA in blood plasma. Results: Comparison of …four different column-based commercial kits shows that the cfDNA purification carried out by the Genomic Mini AX Body Fluids kit and the QIAamp Circulating Nucleic Acid kit gave us the possibility to improve the sensitivity of detection of KRAS mutation and HPV16. The optimized method was used to follow the reduction in cancer-specific cfDNA after therapy. We found that large volume extractions with low volume of DNA eluate enabled trace amounts of tumour-specific cfDNA from cancer patients to be effectively identified. Conclusions: Data presented in this study facilitate detection of tumour-specific cfDNA and improve standards needed for the implementation of cfDNA technology into routine clinical practice. Show more

Keywords: Circulating cell-free DNA, KRAS mutation, human papillomavirus, plasma, cancer, isolation method

DOI: 10.3233/CBM-130371

Citation: Cancer Biomarkers, vol. 13, no. 5, pp. 385-394, 2013

Authors: Lv, Mengmeng | Zhu, Xingya | Chen, Weixian | Zhao, Jianhua | Tang, Jinhai

Article Type: Research Article

Abstract: Background: MicroRNAs (miRNAs) are recognized as potential biomarkers for detection of breast cancer. Many experiments have been done to explore the aberrant expression of circulating miRNAs in breast cancer patients. However, an overwhelming number of miRNAs are identified and some expression characteristics are inconsistent between studies. Objective: To distinguish the candidates for breast cancer detection from spurious miRNAs. Methods: One solution is to take the intersections between studies. As repeated efforts can improve reliability and reduce error, valuable candidate miRNAs in this study are defined as those validated and consistently reported by multiple studies. Data validated …by real-time PCR (RT-PCR) were collected, and the most frequently reported miRNAs with consistent regulation were identified by using a vote-counting strategy based on the number of relevant studies, total sample size and fold change. Results: The top four miRNAs (miR-21, -155, -222and -10b) are consistently regulated in comparisons of the pre-operative patients and the control group. And blood sample type was found to affect the regulation characteristics of miRNAs. Conclusion: MiR-21, -155, -222 and -10b are reliable candidate biomarkers for detection of breast cancer. Show more

Keywords: Breast cancer, microRNA, real time-PCR, biomarker

DOI: 10.3233/CBM-130379

Citation: Cancer Biomarkers, vol. 13, no. 5, pp. 395-401, 2013